Please Wait
Applying Filters...
menu
    • menu
    Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    Eletriptan Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,523Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    29/11/2025 Inke S.A
    Spain
    		 Inke S.A. 304MF10075 Eletriptan hydrobromide 2022-05-18 2022-05-18 Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
    29/11/2025 Inke S.A
    Spain
    		 Inke S.A. 229MF10147 Eletriptan hydrobromide 2017-07-31 2017-07-31 Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN